ArriVent BioPharma, Inc.(AVBP:US)
Market Cap$754.85M
Key Metrics
Price$16.66
Revenue (TTM)$0
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-$145.24M
EBITDA (TTM)-$156.87M
Op. Margin (TTM)-
Dividend Yield-
Holders Yield-
Cash on hand$62.1M
Total Assets$349.3M
Net Assets$323.98M
Total Debt$419K
Key Metrics
Price$16.66
Revenue (TTM)$0
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-$145.24M
EBITDA (TTM)-$156.87M
Op. Margin (TTM)-
Dividend Yield-
Holders Yield-
Cash on hand$62.1M
Total Assets$349.3M
Net Assets$323.98M
Total Debt$419K
Financials
| Name | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| $46.11M | $38.82M | $38.32M | $33.62M | $66.77M | $23.71M | $24.23M | $25.7M | $20.67M | $23.12M | $16.72M | $22.58M | $12.17M | $10.44M | $11.77M | |
| Research and Development | $37.62M | $32.18M | $32.17M | $27.72M | $61.29M | $20.16M | $20.09M | $21.78M | $16.98M | $20.01M | $14.28M | $20.36M | $10.24M | $8.65M | $10.09M |
| Selling, General, and Administrative | $8.49M | $6.65M | $6.15M | $5.9M | $5.48M | $3.54M | $4.14M | $3.92M | $3.7M | $3.11M | $2.44M | $2.23M | $1.94M | $1.8M | $1.68M |
| Other Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income | -$46.11M | -$38.82M | -$38.32M | -$33.62M | -$66.77M | -$23.71M | -$24.23M | -$25.7M | -$20.67M | -$23.12M | -$16.72M | -$22.58M | -$12.17M | -$10.44M | -$11.77M |
| $2.79M | $3.28M | $3.34M | $2.22M | $2.39M | $3.07M | $3.67M | $3.82M | $3.26M | $1.93M | $2.32M | $1.02M | $0 | - | $0 | |
| Non-Operating Interest Income | $2.79M | $3.28M | $3.34M | $2.22M | $2.39M | $3.07M | $3.67M | $3.82M | $3.26M | $1.93M | $2.32M | $1.02M | $0 | - | $0 |
| Non-Operating Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Income/Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Income Before Tax | -$43.32M | -$35.54M | -$34.98M | -$31.4M | -$64.39M | -$20.63M | -$20.56M | -$21.87M | -$17.42M | -$21.19M | -$14.4M | -$21.57M | -$12.17M | -$10.44M | -$11.77M |
Income Tax | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -$43.32M | -$35.54M | -$34.98M | -$31.4M | -$64.39M | -$20.63M | -$20.56M | -$21.87M | -$17.42M | -$21.19M | -$14.4M | -$21.57M | -$12.17M | -$10.44M | -$11.77M |
Minority Interests | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Preferred Stock Dividends | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income to Common | -$43.32M | -$35.54M | -$34.98M | -$31.4M | -$64.39M | -$20.63M | -$20.56M | -$21.87M | -$17.42M | -$21.19M | -$14.4M | -$21.57M | -$12.17M | -$10.44M | -$11.77M |
Shares Outstanding (Basic) | 45.07M | - | 41.91M | 35.01M | 33.9M | - | 33.58M | 33.5M | 25.05M | - | 31.96M | 31.96M | 31.96M | - | - |
Shares Outstanding (Diluted) | 45.07M | - | 41.91M | 35.01M | 33.9M | - | 33.58M | 33.5M | 25.05M | - | 31.96M | 31.96M | 31.96M | - | - |
EPS (Basic) | -$0.96 | - | -$0.83 | -$0.90 | -$1.90 | - | -$0.61 | -$0.65 | -$0.70 | - | -$0.45 | -$0.67 | -$0.38 | - | - |
EPS (Diluted) | -$0.96 | - | -$0.83 | -$0.90 | -$1.90 | - | -$0.61 | -$0.65 | -$0.70 | - | -$0.45 | -$0.67 | -$0.38 | - | - |
EBIT | -$46.11M | -$38.82M | -$38.32M | -$33.62M | -$66.77M | -$23.71M | -$24.23M | -$25.7M | -$20.67M | -$23.12M | -$16.72M | -$22.58M | -$12.17M | -$10.44M | -$11.77M |
EBITDA | -$46.11M | -$38.82M | -$38.32M | -$33.62M | -$66.77M | -$23.71M | -$24.23M | -$25.7M | -$20.67M | -$23.12M | -$16.72M | -$22.58M | -$12.17M | -$10.44M | -$11.77M |